Article
New insights into checkpoint kinase 1 in the DNA damage response signaling network.
Department of Medicine, Institute for Molecular Medicine, and Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia 23298, USA.
Clinical Cancer Research (impact factor:
7.74).
01/2010;
16(2):376-83.
DOI:10.1158/1078-0432.CCR-09-1029
pp.376-83
Source: PubMed
-
Citations (0)
- Cited In (8)
-
Article: Chemotherapeutic targeting of cell death pathways.
[show abstract] [hide abstract]
ABSTRACT: Cell death plays an important role in cancer growth and progression, as well as in the efficiency of chemotherapy. Although apoptosis is commonly regarded as the principal mechanism of programmed cell death, it has been increasingly reported that several anticancer agents do not only induce apoptosis but other forms of cell death such as necrosis, autophagy and mitotic catastrophe, as well as the state of permanent loss of proliferative capacity known as senescence. A deeper understanding of what we know about chemotherapy-induced death is rather relevant considering the emerging knowledge of non-apoptotic cell death signaling pathways, and the fact that many tumors have the apoptosis pathway seriously compromised. In this review we examine the effects that various anti-cancer agents have on pathways involved in the different cell death outcomes. Novel and specific anti-cancer agents directed toward members of the cell death signaling pathways are being developed and currently being tested in clinical trials. If we precisely activate or inhibit molecules that mediate the diversity of cell death outcomes, we might succeed in more effective and less toxic chemotherapy.Anti-cancer agents in medicinal chemistry 01/2012; 12(3):226-38. -
Article: The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.
[show abstract] [hide abstract]
ABSTRACT: Tumours with specific DNA repair defects can be completely dependent on back-up DNA repair pathways for their survival. This dependence can be exploited therapeutically to induce synthetic lethality in tumour cells. For instance, homologous recombination (HR)-deficient tumours can be effectively targeted by DNA double-strand break-inducing agents. However, not all HR-defective tumours respond equally well to this type of therapy. Tumour cells may acquire resistance by invoking biochemical mechanisms that reduce drug action or by acquiring additional alterations in DNA damage response pathways. A thorough understanding of these processes is important for predicting treatment response and for the development of novel treatment strategies that prevent the emergence of therapy-resistant tumours.Nature Reviews Cancer 08/2012; 12(9):587-98. · 29.54 Impact Factor -
Article: Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints.
[show abstract] [hide abstract]
ABSTRACT: Checkpoint kinase 1 (Chk1) is a key regulator of checkpoint signaling in both the unperturbed cell cycle and DNA damage response. Under these conditions, Chk1 becomes active to prevent premature CDK1 activation and mitotic entry until DNA is properly replicated or repaired. It is unclear how Chk1 activity is controlled in the unperturbed cell cycle. During DNA damage, Chk1 is activated by ataxia telangiectasia and Rad3 related (ATR)-mediated phosphorylation; however, it is not entirely clear how this phosphorylation results in Chk1 activation. Here we report an N-terminally truncated alternative splice variant of Chk1, Chk1-S. Importantly, we show that Chk1-S is an endogenous repressor and regulator of Chk1. In the unperturbed cell cycle, Chk1-S interacts with and antagonizes Chk1 to promote the S-to-G2/M phase transition. During DNA damage, Chk1 is phosphorylated, which disrupts the Chk1-Chk1-S interaction, resulting in free, active Chk1 to arrest the cell cycle and facilitate DNA repair. Higher levels of Chk1-S are expressed, along with Chk1, in fetal and cancer tissues than in normal tissues. However, forced overexpression of Chk1-S in cultured cells and tumor xenografts induces premature mitotic entry, mitotic catastrophe, and reduction of tumor growth. The identification of Chk1-S as a unique splice variant and key regulator of Chk1 provides insights into cell cycle regulation and DNA damage response.Proceedings of the National Academy of Sciences 12/2011; 109(1):197-202. · 9.68 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
cell cycle checkpoints
checkpoint kinase 1
chemotherapeutic
Chk1 inhibitor strategies
core component central
DDR machinery
DDR signaling pathways
DDR signaling pathways support
direct involvement
diverse cytotoxic agents
DNA damage response
DNA-damaging agents
entire DDR
mitotic spindle checkpoint
multiple signaling pathways
numerous agents
primary goal
transcriptional programs
various endogenous
various genotoxic insults